Comprehensive HPV Genotyping Test for Early and Accurate Cervical Cancer Detection

Cervical cancer is an entirely preventable form of cancer, yet each year, many women globally continue to suffer due to inadequate services related to early diagnosis and screening. The primary reason for the development of cervical cancer is persistent infection from specific high-risk strains of the Human Papillomavirus (HPV). As new cervical cancer screening methods are introduced in countries worldwide, more emphasis will be placed on testing equipment that provides accurate results with respect to risk levels, including the HPV genotyping test and HPV self-sampling tests, which are becoming increasingly available. The process used to detect the HPV virus is also important, because not all the different types of technologies offer the same level of accuracy.

The Evolution of HPV Testing; Hybrid Capture to PCR Traditionally, many laboratories have been using Hybrid Capture assays to test for HPV (HC2). The Hybrid Capture test uses a signal amplification process that detects the presence of pooled strains of high-risk HPV DNA through RNA probes. Therefore, this type of test is valuable in that it will indicate whether a woman has a positive or negative test for phase high-risk HPV; however, it cannot indicate the actual strain of HPV that is causing the infection.

In contrast, PCR-based HPV assays use Polymerase Chain Reaction technology to amplify specific segments of HPV DNA. This allows for highly sensitive and specific detection, even when the viral load is low. PCR not only detects the presence of HPV but also identifies the exact genotype responsible for the infection. This precision enables better risk assessment, targeted monitoring, and more informed clinical management.

Why PCR-Based HPV Genotyping Is More Efficient

PCR assays are considered superior to Hybrid Capture because they possess advantages on many levels. First, they have much better analytical sensitivity, as PCR can detect far smaller amounts of viral DNA than can other types of assays. Thus, there will be fewer false-negative results with PCR than with other methods, especially in the early or early-stage low-level infections.

Second, PCR also allows for genotype-specific results. Rather than receiving a pooled “high-risk positive” result, one receives an HPV genotyping test result based on whether the woman has HPV 16, HPV 18 or any of the other high-risk types. With this level of detail, doctors will be able to identify which patients are at highest risk for immediate referral for colposcopy or closer follow up.

Finally, PCR assays are very reproducible and adaptable. They can be performed on multiple targets simultaneously in a single run, thus providing an improvement in efficiency and turnaround time...that is particularly useful for large-scale screening programs and population-level cervical cancer prevention strategies.

In addition, for long-term monitoring of patients with potential persistent infection or follow-up after treatment, using PCR-based genotyping will provide significantly greater clarity regarding which patients have persistent infection when compared with using pooled detection methods. Determining whether or not the same genotype is present over time will have a major impact on patient management decisions.

Comprehensive Detection of All 14 High-Risk HPV Types

While many tests focus primarily on HPV 16 and 18, global data shows that other high-risk types such as HPV 31, 33, 35, 45, 52, and 58 also contribute significantly to cervical cancer, particularly in Asian and Indian populations. Therefore, limiting testing to only two genotypes may underestimate true risk.

Greenarray addresses this gap through its validated HPV PCR Genotyping assay, designed to detect all 14 WHO-recognized high-risk HPV types in a single run. By using PCR-based amplification and genotype-specific probes, the assay ensures comprehensive detection and confirmatory results.

Greenarray has internally validated its HPV PCR Genotyping assay to ensure high sensitivity, specificity, reproducibility, and clinical reliability. This validation process ensures that the assay performs consistently across different sample types, including clinician-collected and self-collected specimens. The result is a robust and dependable diagnostic solution that supports accurate cervical cancer risk assessment.

HPV Self Sampling Test: Expanding Access Without Compromising Accuracy

The biggest drawback associated with cervical cancer screening programs is the low level of interest shown by women owing to various reasons like discomfort, personal reasons, and lack of access to healthcare centers. HPV self sampling is one such revolutionizing technology that allows the lady to collect her sample herself in a comfortable and private environment.

What differentiates the system of Greenarray is the fact that samples, which have been collected by the women themselves, have been carried out with the same scientifically proven polymerase chain reaction-based test for human papillomavirus genotyping, which is undertaken for samples collected by clinicians themselves.

Such tests, carried out across the globe, have affirmed that using molecular tests through self-sampling can be comparable to using clinician samples, provided the proper protocols are followed. This makes the HPV self-sampling test a significant tool in boosting the integrity of self-sampling tests.

HPV Genotyping Test vs Conventional HPV Screening

Routine screening tests such as HPV screening tests that utilize pooled detection methods only yield limited information in relation to assessing specific cancer risk. The HPV genotype test, on the contrary, allows for advanced risk assessment since the specific high-risk HPV type is identified. This becomes particularly important in women aged over 30 years, abnormal cytology results, or follow-up on treated cervical lesions.

As PCR-based HPV genotyping facilitates a more individualized screening interval, it eliminates unnecessary invasive procedures for low-risk infections, thus promoting timely intervention for high-risk infections.

Global efforts for the elimination of cervical cancer are focused on the implementation of three core aspects. These are vaccination, screening, and treatment. Molecular diagnostic technologies play a vital role in the achievement of screening targets.

With its validated HPV PCR Genotyping assay that identifies all 14 high-risk HPV types and its HPV self sampling test, Greenarray is making its contribution to precision medicine and accessible healthcare. This comprehensive approach to HPV testing and detection, as well as its genotyping and user-friendly sampling options, represents the future of cervical cancer testing.